Galileo – Biotech Innovation Fund BC USD

Reference Data

ISIN LU2226244361
Valor Number
Bloomberg Global ID
Fund Name Galileo – Biotech Innovation Fund BC USD
Fund Provider IPConcept (Luxemburg) S.A. Zürich, Switzerland
Phone: +352 260248-1
E-Mail: info.lu@ipconcept.com
Web: www.ipconcept.com
Fund Provider IPConcept (Luxemburg) S.A.
Representative in Switzerland IPConcept (Schweiz) AG
Zürich
Phone: +41 044 224 32 09
Distributor(s) Bellecapital AG
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark.
Peculiarities

Fund Prices

Current Price * 35.55 USD 08.05.2025
Previous Price * 36.15 USD 07.05.2025
52 Week High * 65.08 USD 17.07.2024
52 Week Low * 33.21 USD 09.04.2025
NAV * 35.55 USD 08.05.2025
Issue Price * 35.55 USD 08.05.2025
Redemption Price * 35.55 USD 08.05.2025
Closing Price *
Indicative Minimum Price
Fund Assets *** 26,830,755
Unit/Share Assets *** 25,887,424
Trading Information SIX

Performance

YTD Performance -24.31% 30.12.2024
08.05.2025
YTD Performance (in CHF) -31.11% 30.12.2024
08.05.2025
1 month +3.25% 08.04.2025
08.05.2025
3 months -21.11% 10.02.2025
08.05.2025
6 months -37.90% 08.11.2024
08.05.2025
1 year -42.91% 08.05.2024
08.05.2025
2 years -43.46% 08.05.2023
08.05.2025
3 years -43.25% 10.05.2022
08.05.2025
5 years -76.30% 31.03.2021
08.05.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Arcellx Inc 9.99%
Krystal Biotech Inc 9.23%
Alnylam Pharmaceuticals Inc 4.57%
Q32 Bio Inc 4.19%
Stoke Therapeutics Inc 3.51%
Iovance Biotherapeutics Inc 3.45%
Sarepta Therapeutics Inc 2.94%
Silence Therapeutics PLC ADR 2.75%
Rocket Pharmaceuticals Inc 2.75%
Voyager Therapeutics Inc 2.42%
Last data update 31.10.2024

Cost / Risk

TER
TER date
Performance Fee ***
PTR
Max. Management Fee ***
Ongoing Charges *** 0.44%
SRRI ***
SRRI date *** 30.04.2025

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)